

HEOR researcher with strong expertise in protocol writing and real-world evidence studies. Experience identifying and analyzing gaps in product profile to support evidence generation with fit-for-purpose study design. Interested in early use of HEOR to inform study design to optimize patient access and benefit.

HEOR-Related Skills:

- Computer Languages: R, SAS, SQL, VBA
- Modeling: Budget Impact, Partitioned-Survival, Cost-Effectiveness, Cost Calculator
- Datasets: Optum EHR and Clinformatics (Claims), MarketScan, HCUP-NIS

PHARMACEUTICAL INDUSTRY WORK EXPERIENCE

Jul 2022 - Present

Post-Doctoral HEOR Fellow

Bayer Healthcare Pharmaceuticals/CHOICE Institute, Whippany, NJ

- Currently lead study design and protocol development for retrospective EHR study focused on risk characterization and quantification of patients with CKD and T2D
- Leading interpretation of results and dissemination of real-world study characterizing treatment patterns in atrial fibrillation (AF) using both MarketScan and Optum claims data
- Co-lead treatment pattern study in rare oncological condition to better understand positioning of Bayer product in clinical practice in collaboration with internal analytics team
- Co-lead study comparing machine learning algorithm versus traditional guideline-defined risk categories in order to detect high-risk CKD patients earlier in disease progression
- Provided input into brand planning discussions by conducting gap analyses and brainstorming evidence generation ideas for existing and planned indications of newly launched brand
- Provided input and support to two cost calculators for field HEOR use in formulary discussions with large regional payers
- Developed study concept and protocol to investigate physician demographics and prescribing patterns for a pipeline product
- Led development of two abstracts and posters focusing on biomarker testing patterns and treatment differences by race in metastatic colorectal cancer (mCRC)
- Currently support development of claims-based machine learning algorithm to identify patients using claims and survey data
- Leading internal database analysis for early characterization of treated and untreated populations in early pipeline indication of interest
- Currently support early critical care portfolio for data sourcing needs, indication strategy, and understanding of quality measure landscape
- Grasped keen understanding of company processes by attending key US and Global marketing, market access, and HEOR meetings

Sep 2021 – Oct 2021

Payer Access and Strategy Extern

PRECISIONValue, New York, NY

- Created disease burden and resource utilization section of payer value proposition deck for WINLEVI cream
- Identified key messages and objectives of payer value proposition to create an implementation guide for market access field team

Aug 2021 – Sep 2021

Medical Communications Extern

BGB Group, New York, NY

- Created internal slide deck summarizing Cryopyrin-Associated Periodic Syndrome, mechanism of action and clinical data of riloncept, and competitors as an overview for the creative team
- Developed 18 advisor biographies and helped plan logistics for market access advisory boards for ublituximab
- Contacted reimbursement specialists and practice managers nationwide to gauge interest in advising on market access strategies for ublituximab

Jan 2019 – Apr 2019

Medical Affairs Intern

Alnylam Pharmaceuticals, Cambridge, MA

- Developed internal presentation and abstract to support givosiran pricing strategy in Germany after identifying patterns in healthcare resource utilization of Acute Hepatic Porphyria patients in Europe/Germany
- Supported Medical Affairs communication strategy for givosiran through abstract/poster development for neurology and GI congresses
- Contributed to KOL mapping strategy for lumasiran MSLs by identifying physicians with interest in rare Urology diseases
- Developed slides for internal presentations to support medical communication activities across multiple products

ACADEMIC RESEARCH EXPERIENCE

Jul 2022 – Jun 2023

Post-Doctoral HEOR Fellow

University of Washington, CHOICE Institute, Seattle, WA

- Conducted retrospective claims analysis in Marketscan comparing treatment patterns of AF patients with and without evidence of major bleeding
 - Used SAS/SQL to create patient cohort and clean data
 - Used R for propensity-score matching and statistical analyses including cox proportional hazards regression
- Constructed a partitioned-survival model comparing abiraterone, apalutamide, and enzalutamide in metastatic castration sensitive prostate cancer (mCSPC)
 - Built model in Excel and used R to parametrize survival curves, showing abiraterone to be the most cost-effective choice in all scenarios at a \$150,000 WTP threshold
 - Conducted one-way sensitivity analysis (OWSA), probabilistic sensitivity analysis (PSA), and value of information (VOI) analysis
- Wrote protocol to develop a PRO Instrument to Assess the Effect of Nuisance Bleeds on AF Patients for Outcomes Assessment course
- Conducted systematic literature review of apixaban-associated bleeding among AF patients

Aug 2021 – Mar 2022

Pharmacy Student Researcher

- Created budget impact model to quantify possible access concerns with future Alzheimer's Disease therapies; presented poster at AMCP Annual 2022
- Provided medical writing support and poster development for retrospective cross-sectional analysis comparing mortality and HCRU between bladder cancer patients with and without congestive heart failure; awarded "Best Student Pharmacist Poster" AMCP Annual 2021

EDUCATION

Jul 2022 – Jun 2023

Masters in Health Economics and Outcomes Research Candidate (Jun 2023)

University of Washington, Seattle, WA

Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute

Sep 2016 – May 2022

Doctor of Pharmacy (May 2022)

Bachelor of Science in Pharmacy Studies, Minor: Psychology (May 2021)

Northeastern University, Boston, MA

Bouvé College of Health Sciences, School of Pharmacy and Pharmaceutical Sciences

MANUSCRIPTS

Treatment Patterns of Atrial Fibrillation (AF) Patients After Bleeding on Direct-Acting Oral Anticoagulants (DOACs)

Katta A, Carlson J, Hansen R (Submitted to Journal of Managed Care & Specialty Pharmacy Feb 2024)

Implementing a Machine Learning Model to Predict Risk of Chronic Kidney Disease (CKD) Progression

Tangri N, Singh R, Betts KR, Du Y, Gao S, Katta A, Farag Y, Liu H, Chen J, Whitlock R, Mantilla S, Singh AK (In Progress)

SCIENTIFIC PRESENTATIONS

"Metastatic Colorectal Cancer (mCRC) Patients Treated with Later Lines of Treatment (LOT): A retrospective analysis by race and ethnicity in the United States (US) Community Oncology Setting" (*Acceptance Pending*)

Barzi A, Appukkuttan S, Hocum B, Katta A, Cosgrove D, Sruti I, Shi J, Dai W, Patton G, Babajanyan S, Bekaii-Saab T
ISPOR 2024, May 5-8 | Atlanta, GA

"Implementing a Machine Learning Model to Predict Risk of Chronic Kidney Disease (CKD) Progression" (*Acceptance Pending*)

Tangri N, Singh R, Betts KA, Du Y, Gao S, Katta A, Farag Y, Liu H, Chen J, Whitlock R, Mantilla S, Singh AK
ADA 2024, Jun 21-24 | Orlando, FL

"Real-World Biomarker Testing Patterns in Metastatic Colorectal Cancer (mCRC) Patients Treated with Later Lines of Therapy (LOT) in the United States (US) Community Oncology Setting"

Barzi A, Katta A, Hocum B, Appukkuttan S, Cosgrove D, Sruti I, Shi J, Dai W, Patton G, Babajanyan S, Bekaii-Saab T
ASCO GI 2024, Jan 18-20 | San Francisco, CA

"Cost-Effectiveness of Abiraterone, Enzalutamide, and Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Partitioned-Survival Model"

Katta A, Faculty Advisor: Ryan Hansen
ISPOR 2023, May 7-10 | Boston, MA

"Apixaban-Associated Bleeding Among Patients with Atrial Fibrillation: A Systematic Literature Review"

Katta A, Faculty Advisor: Ryan Hansen
Corporate Advisory Board Meeting 2022, Sep 15 | University of Washington, School of Pharmacy

"Identifying Potential Budget Impact Induced Access Concerns with Alzheimer's Therapeutics"

Katta A, Jain S
AMCP 2022, Mar 29-Apr 1 | Chicago, IL

"Hospital Outcomes Associated with Congestive Heart Failure Among Patients with Bladder Cancer in the U.S." (Best Student Poster Award)

Yu D, Park J, Katta A, Gao T, Park SK, Park C
AMCP 2021, Apr 12-16 | Online

"Characteristics of Expanded Access Programs Inclusive of Children in the United States"

Sheth J, Katta A, Skenyon C, Monpara A, Douglass M, Hurd R
DIA 2019, Jun 23-27 | San Diego, CA